CompletedNCT01427608
Medication Combinations to Sustain Improvement in Psychotic Depression
About this title
Read the official source — NCT01427608Medication studyAges 18–85United States + Canada
Understand this study
Who was this study for?
Listed age limits: 18 years to 85 years.
- Listed locations
- Worcester and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 269
- Sponsor
- Weill Medical College of Cornell University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States, Canada
- Age range
- From 18 Years to 85 Years
- Official registry ID
- NCT01427608
- Official title
Show the full official title
Sustaining Remission of Psychotic Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Worcester, United States · White Plains, United States · Pittsburgh, United States
1 more locations
- Toronto, Canada
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Weill Medical College of Cornell University, a university.
Did this study involve medication?
Yes. The study involved medication, including Sertraline + Olanzapine and Sertraline + Placebo.
Who was this study for?
Listed age limits: 18 years to 85 years.
